The shares of Biomea Fusion Inc. (BMEA) have been on a roll ever since the company reported positive data from its ongoing COVALENT-111 trial yesterday.
COVALENT-111 is a phase I/II trial of lead drug candidate BMF-219 in type II diabetes.
The phase I portion of the COVALENT-111 trial in healthy volunteers, designed to assess safety, tolerability, and pharmacokinetics of BMF-219, was successfully completed last October.
The data reported yesterday were from the initial cohorts of patients with type 2 diabetes mellitus enrolled in the phase II portion of its ongoing COVALENT-111 study.
According to the results reported yesterday, in one of the active treatment Cohorts dosed at 100 mg of BMF-219, 89% of patients achieved a reduction in A1c, with 78% of patients achieving at least a 0.5% reduction in A1c, and 56% achieving at least a 1% reduction in A1c. (A1c is the standard for measuring blood sugar management in people with diabetes).
Near-term Catalyst
A phase I trial of BMF-219 in patients with relapsed/refractory multiple myeloma, acute myeloid leukemia, acute lymphocytic leukemia, and diffuse large B-cell lymphoma, dubbed COVALENT-101, is underway. Initial data from the acute myeloid leukaemia cohort of the COVALENT-101 trial is due in the first half of 2023.
Cash position
Biomea ended the year 2022 with cash, cash equivalents, restricted cash, and investments of $113.4 million.
Today, the company announced that it has commenced an underwritten public offering of $125.0 million of shares of its common stock.
BMEA was trading around $9.32 when it was featured on our site on Jan.30, 2023. The stock, which touched an all-time high of $36.67 during intraday trading today, is currently at $34.80, up 13.32%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.